We are working to identify ways to lower barriers for all new applicants to the NIH SBIR and STTR programs. Conferences have the ability to bring people together expressly to share perspectives and exchange expertise, including the lessons of personal experience. That is why I am pleased to announce as a first step in addressing these concerns we will be sponsoring the 2021 HHS Small Business Program Conference with the theme “Diverse Perspectives SEEDing Impactful Innovations.” The meeting will take place virtually April 26-30 and registration is free.
Are you a life science entrepreneur or biomedical researcher looking for seed funding? Are you a stakeholder in a minority-owned business? Are you new to NIH small business programs? If so, make plans today to participate in the 2021 HHS Small Business Program Conference, presented virtually from April 26-30. Registration is free!
Did you know that the NIH’s small business programs (SBIR and STTR) invest over 1 billion dollars into life science and healthcare companies each year? The newly-created Small business Education and Entrepreneurial Development (SEED) office provides grantees with many of the valuable entrepreneurship and commercialization services we have discussed in previous blogs to help them thrive.
The 21st Annual U.S. Department of Health and Human Services (HHS) Small Business Programs Conference, scheduled for April 28-30, 2020 at the Luxor Hotel Las Vegas will be hosted by University of Nevada, Las Vegas (UNLV). The conference will offer over 40 sessions focused on successfully submitting funding applications, approaching potential partners and investors, accessing the technical assistance programs HHS offers to awardees, and discussing specific questions with HHS SBIR/STTR subject-matter experts.
In this next installment of the “All About Grants” podcast series, small business innovators can learn more about programs geared towards women-owned companies or those led by socially or economically disadvantaged groups.
Wondering how to knock that investor pitch out of the park? In this next installment of the “All About Grants” podcast series, small business innovators will get a front row seat to hear how to prepare for private investment. Dr. Ethel Ruben, NIH’s Entrepreneur-In-Residence, steps up to the plate and shares insights on who these investors are, how they decide on what innovations to invest in the biomedical commercial space, and some valuable tips and tricks to improve the accuracy of your investor pitch.
At NIH, we maintain a broad and diverse portfolio of biomedical and behavioral research. To turn discovery into health, promising technologies must move from the laboratory into clinical trials, into the marketplace, into the doctor’s office, and into our every-day lives. A key way to transition promising technologies out of the laboratory is through the commercialization process.
We were pleased to see the interest in our recent blog on the unique number of investigators applying for and receiving NIH research project grants (RPGs). Some of you (through the blog page or through other media) have asked about whether we have similar data for our Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) program. We have generated analogous figures for SBIR and STTR grants, and today’s post shares this investigation of the question, “How many unique researchers are seeking SBIR/STTR funding?” ….
In the rapidly evolving world of modern medicine, it is important that the transition of basic scientific discoveries into new medical treatments takes place with both precision and speed.
NIH’s Small Business Innovative Research (SBIR) and Small Business Technology Transfer (STTR) programs – which I’ve discussed a few times on the blog before – are a key part of NIH’s translational research portfolio. ….
Tom Kalil is Deputy Director for Technology and Innovation in the White House Office of Science and Technology Policy (OSTP). — We are delighted to announce a new collaboration between the National Institutes of Health (NIH) and the National Science Foundation (NSF) to empower entrepreneurial scientists and advance the Lab-to-Market priorities set forth in the President’s Management Agenda. The Federal government invests over $130 billion on research and development (R&D) each year, and the President’s 2015 budget supports a sustained commitment to accelerate the transfer of promising Federally-funded technologies from the laboratory to the commercial marketplace.